Connor, Clark & Lunn Investment Management (CC&L)’s Editas Medicine EDIT Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio EDIT Stock Details EDIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-85,098	Closed	-$397K	–	1495
2024 Q2	$397K	Sell	85,098 -90,457	-52%	-$510K	﹤0.01%	1110
2024 Q1	$1.3M	Buy	175,555 +160,974	+1,104%	+$1.34M	0.01%	800
2023 Q4	$148K	Buy	+14,581	New	+$128K	﹤0.01%	1291
2022 Q4	–	Sell	-240,244	Closed	-$2.94M	–	1275
2022 Q3	$2.94M	Buy	240,244 +4,028	+2%	+$62.8K	0.02%	421
2022 Q2	$2.79M	Buy	236,216 +53,731	+29%	+$720K	0.02%	419
2022 Q1	$3.47M	Buy	182,485 +108,848	+148%	+$2.02M	0.02%	389
2021 Q4	$1.96M	Sell	73,637 -47,448	-39%	-$1.63M	0.01%	539
2021 Q3	$4.97M	Buy	121,085 +14,568	+14%	+$798K	0.03%	342
2021 Q2	$6.03M	Buy	106,517 +47,498	+80%	+$1.75M	0.03%	319
2021 Q1	$2.48M	Buy	+59,019	New	+$3.36M	0.01%	512

Other funds holding EDIT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s EDIT Position: Q3 2024 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Editas Medicine (EDIT) in Q3 2024, closing a stake of 85,098 shares — an estimated $397K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in EDIT in Q1 2021 and held it in 10 quarters. The position peaked at $6.03M in Q2 2021. 230 funds tracked by Wall St. Rank hold EDIT as of Q3 2024.

Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Editas Medicine position as of Q3 2024 after selling out during the quarter.
Connor, Clark & Lunn Investment Management (CC&L) sold 85,098 Editas Medicine shares in Q3 2024, an estimated $397K.
Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Editas Medicine in Q1 2021 and held it in 10 quarters.
Connor, Clark & Lunn Investment Management (CC&L)'s Editas Medicine position peaked at $6.03M in Q2 2021.
230 funds tracked by Wall St. Rank held Editas Medicine as of Q3 2024.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q3 2024, filed 8 Nov 2024.